Thursday, 21 Mar 2019

You are here

Favorable Certolizumab Safety Profile in Pregnancy

Clowse and colleagues have published an extensive review of the certolizumab pegol (CZP) in pregnancy database, and found no evidence that CZP has a teratogenic effect or contributes to fetal harm when compared to the general population. 

CZP is a PEGylated, Fc‐free anti‐TNF approved for use in Crohn's disease, rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.  Studies have shown little to no active placental transfer of CZP from the mother to fetus in utero.  Recent studies have also shown no or miniscule levels of CZP in the breast milk of women during lactation.

This report analyzes prospective and retrospective data on maternal CZP exposure from the UCB safety database through March 2017. Analysis was limited to prospective reports to avoid potential bias. 

Of the 1137 maternal CZP‐exposed prospective pregnancies, 528 (including 10 twin pregnancies) had 538 known outcomes: 459 live births (85.3%), 47 miscarriages (8.7%), 27 elective abortions (5.0%), and 5 stillbirths (0.9%).

A total of 8 major congenital malformations (1.7%) were seen in 459 infants.

The vast majority of these exposures were from patients with RA (n=235) or Crohn's disease (n=195) and during the first trimester (81.2%). Nearly half (44.5%) had CZP exposure during all 3 trimesters of pregnancy.

These findings are reassuring for women of childbearing age who are considering treatment with CZP.

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Lower TNF Inhibitor Persistence in Spondylitis

A claims data analysis shows that only one-third of ankylosing spondylitis (AS) treated with tumor necrosis factor inhibitors (TNFi) therapy remain on their initial drug in the 2 years post initiation.

The Risk of Tuberculosis with TNF Inhibitors

A study from Turkey shows that among 2117 patients treated with a TNF inhibitor (TNFi) the risk of developing TB was 6 fold higher in those treated with a TNFi compared to non-users.

This retrospective cohort study included patients with rheumatoid arthritis (RA), ankylosing spondylitis, juvenile idiopathic arthritis or psoriatic arthritis (PsA) that treated with or without TNFI. The calculated the 2-year RR of TB after TNFi.

Higher Infection Rates for Infliximab in Psoriasis

A prospective study of psoriasis patients from the British Association of Dermatologists Biologic Interventions Register demonstrated that infliximab therapy yielded 2-3 times more serious infection than seen in those treated with non-biologic DMARDs or methotrexate (MTX).

Biomarker Combo Predicts TNF Inhibitor Responses

Based on clinical trial data, patients starting tumour necrosis factor-alpha inhibitors (TNFi) have roughly a two-thirds chance of achieiving a good clinical response. French investigators have studied a series of potential biomarkers and surmised that the combination of baseline prealbumin, platelet factor 4 and S100A12 can predict a 78% response to TNFi in rheumatoid arthritis (RA) patients.

TNF Inhibitors Don't Increase Cancer Risk in Children

While the risk of neoplasia with tumour necrosis factor inhibitor (TNFi) use has been largely nullified in most inflammatory disorders, this risk in children is less certain. However a recent study shows no risk of increased cancer in children treated with TNFi for juvenile idiopathic arthritis (JIA), pediatric inflammatory bowel disease (pIBD) and pediatric plaque psoriasis (pPsO).